ABCL

AbCellera Biologics Inc. NASDAQ

Healthcare ·Biotechnology ·CA · abcellera.com

$4.59

Mkt Cap $1.4B

52w Low $1.94 57.9% of range 52w High $6.51

50d MA $3.62 200d MA $4.14

P/E (TTM) -9.0x

EV/EBITDA -6.5x

P/B 1.2x

Debt/Equity 0.1x

ROE -15.1%

P/FCF -5.9x

RSI (14) —

ATR (14) —

Beta 0.85

50d MA $3.62

200d MA $4.14

Avg Volume 4.1M

About

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCelle…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 24, 2026	AMC	-0.18	-0.03	+83.3%	3.22	+4.3%	-0.9%	+11.5%	+12.1%	+18.6%	+15.2%	+4.0%	—
Nov 6, 2025	AMC	-0.17	-0.19	-11.8%	4.53	-16.1%	-13.7%	-11.0%	-11.5%	-12.4%	-20.1%	-20.8%	—
Aug 7, 2025	AMC	-0.17	-0.12	+29.4%	4.24	+13.7%	+0.2%	+6.1%	+0.7%	+8.0%	+6.1%	-1.7%	—
May 8, 2025	AMC	-0.17	-0.15	+11.8%	2.01	+2.5%	+1.0%	+2.5%	+4.5%	+2.0%	+0.5%	+24.9%	—
Feb 27, 2025	AMC	-0.15	-0.11	+26.7%	2.92	-6.8%	-11.3%	-19.2%	-19.9%	-18.2%	-18.5%	-23.6%	—
Nov 4, 2024	AMC	-0.14	-0.17	-21.4%	2.89	-13.5%	-5.9%	-4.5%	-5.9%	-6.6%	+9.0%	+0.3%	—
Aug 6, 2024	AMC	-0.15	-0.13	+13.3%	2.85	-3.5%	-7.7%	-2.8%	-6.0%	-7.4%	-6.3%	-14.7%	—
May 7, 2024	AMC	-0.16	-0.14	+12.5%	4.04	+0.0%	-5.0%	-2.2%	-5.2%	-4.7%	-5.4%	-6.4%	—
Feb 20, 2024	AMC	-0.14	-0.17	-21.4%	5.31	-1.1%	-9.4%	-8.7%	-8.3%	-6.8%	-3.6%	-11.3%	—
Nov 2, 2023	AMC	-0.14	-0.10	+28.6%	4.43	-10.4%	+6.1%	+1.0%	-0.7%	-5.6%	-8.8%	+4.7%	—
Aug 3, 2023	AMC	-0.13	-0.11	+15.4%	6.97	-6.5%	-13.3%	-16.1%	-15.5%	-13.6%	-15.6%	-20.4%	—
May 4, 2023	AMC	-0.12	-0.14	-16.7%	6.61	-3.0%	-9.4%	-13.6%	-14.4%	-10.9%	-13.2%	+3.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Nov 7	Leerink Partners	Downgrade	Outperform → Market Perform	—	$4.53	$3.80	-16.1%	-13.7%	-11.0%	-11.5%	-12.4%	-20.1%
Aug 8	Stifel	Maintains	Buy → Buy	—	$4.24	$4.82	+13.7%	+0.2%	+6.1%	+0.7%	+8.0%	+6.1%
Jul 14	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$4.01	$4.01	+0.0%	+5.7%	-1.7%	+1.2%	-2.7%	+11.7%
May 16	Truist	Maintains	Buy → Buy	—	$2.02	$2.03	+0.5%	+0.5%	+0.0%	+3.5%	-1.5%	-1.0%
May 9	Stifel	Maintains	Buy → Buy	—	$2.01	$2.06	+2.5%	+1.0%	+2.5%	+4.5%	+2.0%	+0.5%
Apr 16	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$2.43	$2.45	+0.8%	-1.6%	-0.4%	+0.8%	+3.7%	+4.1%
Mar 3	Benchmark	Maintains	Hold → Hold	—	$2.59	$2.61	+0.8%	-8.9%	-9.7%	-7.7%	-8.1%	-10.0%
Feb 28	Stifel	Maintains	Buy → Buy	—	$2.92	$2.72	-6.8%	-11.3%	-19.2%	-19.9%	-18.2%	-18.5%
Jan 8	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$3.28	$3.26	-0.6%	-7.6%	-11.0%	-8.5%	-15.5%	-9.8%
Nov 5	Stifel	Maintains	Buy → Buy	—	$2.89	$2.50	-13.5%	-5.9%	-4.5%	-5.9%	-6.6%	+9.0%
Aug 20	Benchmark	Downgrade	Buy → Hold	—	$2.71	$2.64	-2.6%	-4.1%	-2.6%	-7.4%	-3.7%	-0.7%
Jul 11	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$2.80	$2.91	+3.9%	+11.8%	+11.4%	+14.3%	+24.6%	+20.4%
May 8	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$4.04	$4.04	+0.0%	-5.0%	-2.2%	-5.2%	-4.7%	-5.4%
Feb 22	Benchmark	Upgrade	Hold → Buy	—	$4.81	$5.03	+4.6%	+0.8%	+1.2%	+2.9%	+6.4%	+5.6%
Feb 21	Stifel	Maintains	Buy → Buy	—	$5.31	$5.25	-1.1%	-9.4%	-8.7%	-8.3%	-6.8%	-3.6%
Aug 31	Benchmark	Maintains	Buy → Buy	—	$5.80	$5.79	-0.2%	-6.0%	-3.6%	-4.3%	-5.0%	-4.1%
Aug 4	Goldman Sachs	Maintains	Buy → Buy	—	$6.97	$6.52	-6.5%	-13.3%	-16.1%	-15.5%	-13.6%	-15.6%
May 5	Credit Suisse	Maintains	Outperform → Outperform	—	$6.61	$6.41	-3.0%	-9.4%	-13.6%	-14.4%	-10.9%	-13.2%
Feb 28	Cowen & Co.	Maintains	Outperform → Outperform	—	$8.43	$8.49	+0.7%	-0.4%	-3.3%	-3.0%	-0.6%	-3.9%
Feb 22	BMO Capital	Maintains	Outperform → Outperform	—	$8.89	$8.70	-2.1%	-1.1%	-4.3%	-5.8%	-5.2%	-5.5%
Feb 22	Credit Suisse	Maintains	Outperform → Outperform	—	$8.89	$8.70	-2.1%	-1.1%	-4.3%	-5.8%	-5.2%	-5.5%
Jan 6	SVB Leerink	Maintains	Outperform → Outperform	—	$9.65	$9.70	+0.5%	-1.5%	-1.0%	-2.8%	-0.5%	+5.7%
Dec 15	Goldman Sachs	Maintains	Buy → Buy	—	$10.13	$11.14	+10.0%	+2.7%	+0.8%	-1.9%	+2.8%	+4.6%
Nov 16	Truist	Maintains	Buy → Buy	—	$14.49	$14.73	+1.7%	+0.2%	-2.8%	-2.3%	-3.0%	-3.5%
Nov 9	SVB Leerink	Maintains	Outperform → Outperform	—	$12.24	$12.99	+6.1%	-3.5%	+5.5%	+10.9%	+16.6%	+18.4%
Aug 10	Credit Suisse	Maintains	Outperform → Outperform	—	$11.11	$10.72	-3.5%	+20.1%	+20.3%	+23.1%	+21.9%	+14.8%
Jul 26	Piper Sandler	Maintains	Overweight → Overweight	—	$10.10	$10.11	+0.1%	+0.9%	+4.1%	+3.3%	-0.6%	+0.4%
May 11	Piper Sandler	Maintains	Overweight → Overweight	—	$6.64	$6.96	+4.8%	-13.9%	+1.1%	+8.9%	+17.6%	+22.7%
May 11	SVB Leerink	Maintains	Outperform → Outperform	—	$6.64	$6.96	+4.8%	-13.9%	+1.1%	+8.9%	+17.6%	+22.7%
Feb 25	Credit Suisse	Maintains	Outperform → Outperform	—	$8.45	$9.36	+10.8%	+5.7%	+3.1%	+7.0%	+11.6%	+7.0%
Feb 25	SVB Leerink	Maintains	Outperform → Outperform	—	$8.45	$9.36	+10.8%	+5.7%	+3.1%	+7.0%	+11.6%	+7.0%
Dec 21	Benchmark	Maintains	Buy → Buy	—	$14.60	$14.92	+2.2%	+7.8%	+5.5%	+2.3%	+1.0%	-6.1%
Nov 19	Piper Sandler	Maintains	Overweight → Overweight	—	$15.31	$15.57	+1.7%	+3.2%	-5.8%	-8.8%	-5.7%	-8.6%
Aug 13	Credit Suisse	Maintains	Outperform → Outperform	—	$15.19	$15.00	-1.3%	+17.8%	+16.3%	+9.2%	+10.3%	+4.0%
May 14	Credit Suisse	Maintains	Outperform → Outperform	—	$34.14	$31.75	-7.0%	-7.0%	+0.1%	-3.4%	-5.2%	-6.9%
Mar 30	Stifel	Maintains	Buy → Buy	—	$23.29	$27.52	+18.2%	+14.6%	+45.8%	+31.9%	+20.6%	+24.5%
Feb 8	SVB Leerink	Maintains	Outperform → Outperform	—	$46.55	$49.00	+5.3%	-3.3%	+1.0%	+0.9%	-1.2%	-7.7%
Jan 5	BMO Capital	Maintains	Outperform → Outperform	—	$39.10	$38.81	-0.7%	-1.5%	+1.3%	+0.6%	+1.6%	-6.4%

Recent Filings

8-K · 7.01 ! Medium

AbCellera Biologics Inc. Common Shares -- 8-K 7.01: Regulation FD Disclosure

AbCellera will present 2025 financial results and corporate updates during its February 24, 2026 earnings call using a prepared presentation.

Feb 24

Data updated apr 24, 2026 10:12am · Source: massive.com